Literature DB >> 8135492

Oncogene regulation by growth factors.

J J Hsuan1.   

Abstract

Complementary studies on quite different eukaryotic systems are revealing that certain mitogenically important enzymes, that were previously assigned to unrelated metabolic pathways, bind and may be regulated by receptor tyrosine kinases (RTKs). A deeper understanding of the relationships between these signalling pathways promises to improve our attempts to rationalise important properties of the transformed phenotype, such as tumour growth rates, metastasis and mechanisms of cellular transformation, and thereby, it is hoped, improve prognostic, diagnostic and treatment regimes. This review briefly summarises results from our and other laboratories that have shed light on specific intracellular signalling enzymes that respond to stimulation by RTKs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8135492

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

Review 1.  Growth factors in bladder cancer.

Authors:  M Liebert
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

2.  The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis.

Authors:  M Zhou; M T Mok; H Sun; A W Chan; Y Huang; A S Cheng; G Xu
Journal:  Oncogene       Date:  2017-03-20       Impact factor: 9.867

Review 3.  EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy.

Authors:  Cristina Zahonero; Pilar Sánchez-Gómez
Journal:  Cell Mol Life Sci       Date:  2014-03-27       Impact factor: 9.261

4.  Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study.

Authors:  G P Stathopoulos; D Trafalis; J Dimitroulis; A Athanasiou; J Koutantos; A Anagnostopoulos
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

5.  CSN6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR.

Authors:  J Hou; Q Deng; J Zhou; J Zou; Y Zhang; P Tan; W Zhang; H Cui
Journal:  Oncogene       Date:  2016-08-22       Impact factor: 9.867

6.  Prediction of inhibitory activity of epidermal growth factor receptor inhibitors using grid search-projection pursuit regression method.

Authors:  Hongying Du; Zhide Hu; Andrea Bazzoli; Yang Zhang
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

7.  The Hippo transducer TAZ promotes cell proliferation and tumor formation of glioblastoma cells through EGFR pathway.

Authors:  Rui Yang; Yanan Wu; Jiahua Zou; Ji Zhou; Mei Wang; Xiangwei Hao; Hongjuan Cui
Journal:  Oncotarget       Date:  2016-06-14

8.  The Effect of Canertinib on Sensitivity of Cytotoxic Drugs in Tamoxifen-Resistant Breast Cancer Cells In Vitro.

Authors:  Hesham A M Gomaa; Asmaa T Ali; M Abdel Gabbar; M A Kandeil
Journal:  Int J Genomics       Date:  2018-10-23       Impact factor: 2.326

9.  HDAC9 promotes glioblastoma growth via TAZ-mediated EGFR pathway activation.

Authors:  Rui Yang; Yanan Wu; Mei Wang; Zhongfeng Sun; Jiahua Zou; Yundong Zhang; Hongjuan Cui
Journal:  Oncotarget       Date:  2015-04-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.